The first generation of gene therapy for hemophilia, called gene insertion or gene addition, is now a reality, but it is not for everyone. Dr. Glenn Pierce explores other approaches to gene therapy in the research pipeline that in the future may be more efficacious for a longer time for more people. Glenn is a long-time researcher in coagulation products for hemophilia and is currently the Medical Vice President of the World Federation of Hemophilia.

Canadian Hemophilia Society

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.